Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olokizumab (Primary) ; Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDO 2
  • Sponsors R-Pharm

    • Most Recent Events

    • 15 Nov 2023 Results (n=1944) assessing the changes in serum adiponectin levels in patients with active rheumatoid arthritis during treatment with IL-6 inhibitor olokizumab from NCT02760368; NCT02760407; NCT02760433 trials, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results (n=1402) assessing the Impact of comorbidities on the efficacy of Il-6 Inhibitor olokizumab compared to adalimumab presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results (n=1402) assessing impact of comorbidity burden on the efficacy of IL-6 inhibitor olokizumab (OKZ) and TNF-a inhibitor adalimumab (ADA) in the CREDO-2 clinical trial cohort of patients with active rheumatoid arthritis (RA), presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top